Duke Banks $129 Million in Federal Funding for HIV Vaccine R&D: To Include HIV Vaccine Manufacturing Facility

Medical stethoscope. TrialsiteN

Duke Human Vaccine Institute (DHVI) continues its 14-year-long effort to develop a vaccine for HIV. The National Institute of Allergy and Infectious Disease (NIAID) has announced a several-year $129 million grant for the ongoing vaccine development by DHVI. Under the deal terms, DHVI could secure an additional $18 million for a grand total of up to $147 million.

Duke Consortia for HIV/AIDS Vaccine Development (CHAVD)

This public funding contributes to this ongoing CHAVD initiative, which has received two previous federal grants including:

  •         $350 million in 2005
  •         $139 million in 2012

A grand total of $618 million have been awarded to this prestigious North Carolina academic research center reports the Triangle Business Journal.

Research Center Comment

Reporting out of Research Triangle out of North Carolina, Seth Thomas Gulledge secured a quote from Dr. Barton Haynes, director of DHVI who stated, “We have been fortunate over the past 14 years to have the resources to learn what roadblocks HIV presents, and to map a path that might lead to a successful vaccine.” Moreover, he continued “We are grateful to receive this new grant to now work toward manufacturing potential vaccines and testing them in animal studies and in carefully designed and monitored trials with human participants.”

Ongoing Challenges with HIV

Daily medication now exists to suppress HIV to undetectable levels in the blood and can prevent sexual transmission of the virus but a vaccine ultimately is required to prevent 1.8 million newly infected patients each year.

CHAVD Represents the US and Europe Collaborative

CHAVD is far more than just DHVI but represents a globally collaborative enterprise constituting HIV researchers operating in both the U.S. and Europe.  Projects and associated research activities are centered around vaccine development. Duke is the nexus of this effort and will also set up a manufacturing facility for vaccine production—apparently the first and only such facility at an academic medical center dedicated to HIV vaccine production.

Lead Research/Investigator

Dr. Barton Haynes